X

Trial Profile

Deliver Insights in Hypertrophic Cardiomyopathy and Observational Outcomes in Real World: United States Prospective Registry Study

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 05 Aug 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Mavacamten (Primary) ; Beta adrenergic receptor antagonists; Disopyramide
Indications Hypertrophic cardiomyopathy
Focus Therapeutic Use
Acronyms DISCOVER-HCM
Sponsors Bristol-Myers Squibb

Most Recent Events

12 Oct 2022 Planned End Date changed from 31 Jul 2029 to 15 Aug 2029.
12 Oct 2022 Planned primary completion date changed from 31 Jul 2029 to 15 Aug 2029.
12 Oct 2022 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com